Merck & Co Inc (NYSE:MRK)
| 90.97 Delayed Data As of Jan 17 |  -0.21 / -0.23%Today’s Change | 72.05 Today|||52-Week Range 92.64 | +0.02% Year-to-Date |
Latest MRK News | Press Releases
| Here's Why Clovis Oncology Rose as Much as 25.6% Today Jan 15 / MotleyFool.com - Paid Partner Content | Merck's Blockbuster Drug Wins Key New FDA Approval Jan 08 / MotleyFool.com - Paid Partner Content |
| FDA Gives Clovis Oncology's Rubraca a Priority Review Jan 15 / MotleyFool.com - Paid Partner Content | The Risk of Cancer-Related Death Is Dropping Faster Than Ever Jan 08 / MotleyFool.com - Paid Partner Content |
| Better Buy: Johnson & Johnson vs. Merck Jan 15 / MotleyFool.com - Paid Partner Content | Dollar Tree Stock Is Down 20%, But Investors Should Reject Mini-Tender Offer Jan 08 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 91.18 |
| Today’s open | 91.28 |
| Day’s range | 90.86 - 91.63 |
| Volume | 9,667,383 |
| Average volume (3 months) | 8,252,565 |
| Market cap | -- |
Data as of 6:30pm ET, 01/17/2020
Growth & Valuation
| Earnings growth (last year) | +165.32% |
| Earnings growth (this year) | +19.21% |
| Earnings growth (next 5 years) | +9.00% |
| Revenue growth (last year) | +6.17% |
| P/E ratio | 25.4 |
| Price/Sales | 4.82 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| PFEPfizer | -0.10 | -0.25% |
| NVSNovartis | +0.83 | +0.87% |
| BMYBristol-Myers Squibb | -0.06 | -0.09% |
| AZNAstraZeneca | +0.82 | +1.62% |
Data as of 6:30pm ET, 01/17/2020
Financials
| Next reporting date | February 5, 2020 |
| EPS forecast (this quarter) | $1.15 |
| Annual revenue (last year) | $42.4B |
| Annual profit (last year) | $6.2B |
| Net profit margin | 14.65% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Kenilworth, New Jersey |
Forecasts
